Table 2. Simultaneous medications related with CVD by ADT exposure.
| ADT not used (N=5467) | ADT used (N=2170) | Total (N=7637) | P-value | |
|---|---|---|---|---|
|
Antiarrthymics | ||||
| No | 5457 (99.8) | 2162 (99.6) | 7619 (99.8) | 0.1311 |
| Yesa | 10 (0.2) | 8 (0.4) | 18 (0.2) | |
|
Anticoagulants | ||||
| No | 5182 (94.8) | 1978 (91.2) | 7160 (93.8) | <0.0001 |
| Yesa | 285 (5.2) | 192 (8.8) | 477 (6.2) | |
|
Antihypertensives | ||||
| No | 5201 (95.1) | 2064 (95.1) | 7265 (95.1) | 0.9719 |
| Yesa | 266 (4.9) | 106 (4.9) | 372 (4.9) | |
|
Antilipemics | ||||
| No | 3653 (66.8) | 1187 (54.7) | 4840 (63.4) | <0.0001 |
| Yesa | 1814 (33.2) | 983 (45.3) | 2797 (36.6) | |
|
Calcium channel blockers | ||||
| No | 5004 (91.5) | 1902 (87.6) | 6906 (90.4) | <0.0001 |
| Yesa | 463 (8.5) | 268 (12.4) | 731 (9.6) | |
|
Antidiabetic drugs | ||||
| No | 5090 (93.1) | 1928 (88.8) | 7018 (91.9) | <0.0001 |
| Yesa | 377 (6.9) | 242 (11.2) | 619 (8.1) | |
|
Digoxin/lanoxin | ||||
| No | 5364 (98.1) | 2092 (96.4) | 7456 (97.6) | <0.0001 |
| Yesa | 103 (1.9) | 78 (3.6) | 181 (2.4) | |
|
Nitrates | ||||
| No | 5232 (95.7) | 1982 (91.3) | 7214 (94.5) | <0.0001 |
| Yesa | 235 (4.3) | 188 (8.7) | 423 (5.5) | |
Abbreviations: ADT=androgen deprivation therapy; CVD=cardiovascular disease. P-value based on Pearson’s chi-square test, two-sided.
a
Yes: there are at least two consecutive prescriptions within 90 days.